“We need to continue antiviral therapy and maintain vigilance for risk of progressive liver disease in our HBV/HIV-coinfected patients as the new assays suggest that continued disease activity occurs despite apparently suppressed HBV replication using available treatment.” Raymond T. Chung, MD